A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
Active, not recruiting · NCT07713290 · Registry updated 2026-07-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 1 | 2026-07-20 | NCT07713290 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Gene Key Life Technology Co., Ltd | 5 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Ditan Hospital, Capital Medical University | Beijing | China | 9 |
| Beijing You An Hospital | Beijing | China | 1 |
| First Hospital of Shanxi Medical University | Taiyuan | China | 16 |